Cardiol Therapeutics (TSE:CRDL) has released an update.
Cardiol Therapeutics Inc. reported a decrease in total assets from CAD 36.7 million as of December 31, 2023, to CAD 26.3 million as of June 30, 2024, while total liabilities slightly increased from CAD 8.45 million to CAD 10.95 million. The company’s net loss for the six months ended June 30, 2024, was CAD 15.77 million, a slight increase from the CAD 14.56 million net loss in the same period of the previous year. These financial results reflect the ongoing research and development efforts as well as general administrative expenses during the period.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
